Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

TVGNNYSE / NASDAQHealthcareSmall cap

$5.90-$0.40 (-6.3%)

Last close · Data as of Nov 20, 2026

Market cap
$41.3M
P/E
-1.6x
EV / EBITDA
-1.9x
Revenue
$0.00
ROCE
973.4%

-71.4% over the last year

Tevogen Bio Holdings Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-13.5%
3M
-7.4%
6M
-43.7%
1Y
-71.4%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$0.40 (-6.3%) from $6 to $6 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TVGN, bought on each weekday since 2022.

News & filings

What Tevogen Bio Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths

No strength stands out for this company on the data on file.

  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.

Read moreShow less

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Sector
Healthcare
Shares outstanding
4.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$41.3M
P/E
-1.6x
P/B
-2.4x
EV / EBITDA
-1.9x
52-week high
$24.05
52-week low
$3.89

Profitability

ROE
154.2%
ROCE
973.4%
ROA
-599.5%

Growth

Revenue
$0.00
Net profit growth, 1Y
91.4%
Free cash flow
-$12.4M

Solvency

Current ratio
0.22
Debt / Equity
-0.44
Debt / Assets
1.71
CFO / Net profit
0.47
Cash / Market cap
1.3%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Tevogen Bio Holdings Inc. revenue and net profit by fiscal year
Tevogen Bio Holdings Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00$4.4M
FY2023$0.00-$60.5M
FY2024$0.00-$13.7M
FY2025$0.00-$26.3M

Cash flows

FY2025: -$12.3M from operations, -$12.4M free after investment (dashed).

Tevogen Bio Holdings Inc. operating and free cash flow by fiscal year
Tevogen Bio Holdings Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$215.4k-$215.4k
FY2023-$8.2M-$8.3M
FY2024-$12.0M-$12.0M
FY2025-$12.3M-$12.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$25.6M
Net profit
-$26.3M
Cash from operations
-$12.3M
Free cash flow
-$12.4M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$25.6M-$26.3M-$12.4M154.2%—+91.4%

Monthly returns

Month-by-month returns of TVGN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$4.4M
Liabilities$12.6M
Equity-$8.2M
Paid-in capital$122.6M
Retained earnings-$139.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TVGN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Tevogen Bio Holdings Inc., Actuate Therapeutics, Inc. Common stock, Tvardi Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Tevogen Bio Holdings Inc.TVGNthis company$41.3M-1.6x-2.4x154.2%-1.9x
DocGo Inc.DCGO$56.3M-0.3x0.4x-126.7%-0.5x
aTyr Pharma, Inc.ATYR$50.3M-0.7x0.7x-109.8%-0.7x
Myomo, Inc.MYO$49.8M-3.2x4.4x-136.6%-4.4x
Actuate Therapeutics, Inc. Common stockACTU$46.4M-2.1x5.9x-280.5%—
Accuray IncorporatedARAY$43.5M-27.3x0.5x-2.0%8.0x
Gossamer Bio, Inc.GOSS$41.7M-0.2x-0.3x138.8%-1.3x
INmune Bio Inc.INMB$35.9M-0.8x1.5x-195.3%-0.4x
Tvardi Therapeutics, Inc.TVRD$28.9M-1.6x1.4x-87.0%-0.3x
Peer median—-1.2x1.1x-118.2%-0.5x

Year-to-date ROI

TVGN since 1 January, against earlier years.

Historical volatility

TVGN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$26.1M
Research and developmentResearch And Development$11.1M
Total expensesTotal Expenses$26.1M
Pretax incomePretax Income-$26.3M

Learn while you research

Academy chapters picked for Tevogen Bio Holdings Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →